期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

P15^(INK4B)基因甲基化与骨髓增生异常综合征 被引量：1

下载PDF
导出
摘要 骨髓增生异常综合征(MDS)是一种造血干细胞的克隆性疾病,容易进展为急性白血病。P15^(INK4B)基因为人类肿瘤抑制基因,在负向调节造血细胞增生和阻止其恶性转换中起着重要的作用。近来研究显示P15^(INK4B)基因高度甲基化与MDS的发生、发展具重要关系,越是疾病进展期,P15^(INK4B)基因甲基化出现越频繁。5-氮杂胞苷(5-azacytidine)和5-杂氮-2’-脱氧胞嘧啶(decitabine)用于治疗MDS患者已取得一定效果,三氧化二砷的体外试验显示其具有抑制MDS细胞株生长和去甲基化作用。去甲基化治疗有望成为今后治疗MDS的有效方案之一。
作者 叶雪石 刘霆
机构地区 四川大学华西医院血液内科
出处 《国外医学（输血及血液学分册）》 2004年第1期63-66,共4页 Foreign Medical Sciences(Section of Blood Transfusion and Heanatology)
关键词 P15^INK4B基因 甲基化 骨髓增生异常综合征 造血干细胞 克隆性疾病 肿瘤抑制基因
分类号 R551.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献16

  • 1Preisler HD,Li B,Chen H,et,al.P15INK4B gene methylation and expression in normal,myelodysplastic,and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients.Leukemia,2001,15(10):1589-1595.
  • 2Tien HF,Tang JH,Tsay W,et al.Methylation of the p15(INK4B) gene in myelodysplastic syndrome:it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation.Br J Haematol,2001,112(1):148-154.
  • 3Uchida T,Kinoshita T,Nagai H,et al.Hypermethylation of the P15INK4B gene in myelodysplastic syndromes.Blood,1997,90(4):1403-1409.
  • 4Silverman LR.Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS).Oncologist,2001,6(Suppl)5:8-14.
  • 5Daskalakis M,Nguyen TT,Nguyen C,et al.Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine)treatment.Blood,2002,100(8):2957-2964.
  • 6Silverman LR,Holland JF,Weinberg RS,et al.Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.Leukemia,1993,7(Suppl 1):21-29.
  • 7Silverman LR,Holland JF,Demakos EP,et al.Azacytidine (aza C) in myelodysplastic syndromes (MDS):CALGb studies 8421and 8921.AnnHematol,1994,68:A12.
  • 8Cheson BD.Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes.Leuk Res,1998,22(Suppl 1):S17-S21.
  • 9Mace JM,Wang LJ.Arsenic alters cytosine methylation patterns of the promoter of the tumor supressor gene P53 in human lung cells:a model for a mechanism of carcinogenesis.Mutat Res,1997,386:263-277.
  • 10Quesnel B,Guillerm G,Vereecque R,et al.Methylation of the P15INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression.Blood,1998; 91:2985-2990.

二级参考文献9

  • 1Macc JM, Wang LJ. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene P53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res, 1997, 386: 263-277.
  • 2Steube KG, Gignac SG, Hu ZB, et al. In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line Mutz-1. Leuk Lymphoma, 1997, 25: 345-363.
  • 3Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG island. Proc Natl Acad Sci U S A, 1996,93:9821-9826.
  • 4Toyota M, Kopecky KJ, Yoyota MO, et al. Methylation profiling in acute myeloid leukemia. Blood, 2001,97: 2824-2829.
  • 5Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood, 2001, 97: 1172-1179.
  • 6Tian HF, Tang JL, Tsay W, et al. Methylation of the P15INK4b gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukemia transformation. Br J Haematol, 2001, 112:148-154.
  • 7Lin C, Hsieh SY, Sheen IS, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res, 2001,61:4238-4243.
  • 8Ahlumwalisa A, Hurteau JA, Bigsby RM, et al. DNA methylation of ovarian cancer. Ⅱ. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol, 2001, 82:299-304.
  • 9朱新华,陈国强.砷剂对肿瘤的生物学作用[J].国外医学（输血及血液学分册）,1998,21(5):314-316. 被引量：17

共引文献16

同被引文献22

  • 1Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controver- sies. LeukRes, 2003, 27(2): 95-120.
  • 2Matarazzo MR, De Bonis ML, StrazzuUo M, Cerase A, Ferraro M, Vastarelli P, Ballestar E, Esteller M, Kudo S, D'Esposito M. Multiple binding of methyl-CpG and poly- comb proteins in long-term gene silencing events. J Cell Physiol, 2007, 210(3): 711-719.
  • 3Issa JP. Epigenetic changes in the myelodysplastic syn- drome. Hematol Oncol Clin North Am, 2010, 24(2): 317-330.
  • 4Zhou L, Opalinska J, Sohal D, Yu YT, Mo YK, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang JH, Kambhampati S, Parmar S, Nischal S, Hueck C, Suzuki M, Freidman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, McMahon C, Gore SD, Pla- tanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma A. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a can- didate pathogenic gene on chromosome 7q. J Biol Chem, 2011, 286(28): 25211-25223.
  • 5Wu XQ, Liu WL, Tian Y, Xiao M, Wu Y, Li CR. Aberrant Methylation of Death-Associated Protein Kinase 1 CpG Islands in Myelodysplastic Syndromes. Acta Haematol, 2011, 125(4): 179-185.
  • 6Fabiani E, Leone G, Giachelia M, D'alo' F, Greco M, Criscuolo M, Guidi F, Rutella S, Hohaus S, Voso MT. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. LeukLymphoma, 2010, 51(12): 2275-2284.
  • 7Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15^INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia, 2003, 17(9): 1813- 1819.
  • 8Shen LL, Kantarjian H, Guo Y, Lin E, Shan JQ, Huang XL, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JPJ. DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes. J Clinical Oncol, 2010, 28(4): 605-613.
  • 9Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxieol, 2011, 7(5): 661-672.
  • 10Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One, 2011, 6(3): e17388.

引证文献1

二级引证文献2

国外医学（输血及血液学分册）
2004年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部